A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
Latest Information Update: 27 Mar 2025
At a glance
- Drugs VC 005 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Jiangsu Vcare Pharmatech
- 27 Mar 2025 New trial record